论文部分内容阅读
目的 探讨药物控制释放载体与组织工程载体的制备方法与结构形态。方法 用新型生物可降解材料聚羟基丁酸酯-羟基戊酸酯共聚物[poly(hydroxybutyrate-hydroxyvalerate) PHBV]、聚己内酯[poly(ε-caprolatone), PCL]及其共混物为基材，用乳化-溶剂蒸发法制备不同结构形态微球。结果 平均粒径为30.5μm，粒径分布较窄（跨距SPAN=1.18），呈正态曲线分布。扫描电镜观察, PHBV微球表面呈不规则多孔皱缩结构形态; PCL微球表面光滑，无孔洞；PCL/PHBV共混微球呈有规则多孔洞形态结构，随着基材中PCL成分增加，微球孔洞大小与数目也随之增加。结论 通过选择不同生物材料及共混方法，改变微球的结构形态，以满足不同药物释放系统与组织工程对载体性能与形态的不同要求。
Objective To investigate the preparation method and structure of drug controlled release vector and tissue engineering vector. Methods Poly (hydroxybutyrate-hydroxyvalerate) (PHBV), poly (ε-caprolatone) (PCL) and their blends were used as the base materials of new biodegradable materials The microspheres with different structures were prepared by emulsion - solvent evaporation method. Results The average particle size was 30.5μm, the particle size distribution was narrower (span SPAN = 1.18), which showed a normal curve distribution. Scanning electron microscopy showed that the surface of the PHBV microspheres was irregular porous shrinkage structure. The surface of PCL microspheres was smooth and non-porous. PCL / PHBV hybrid microspheres showed the morphology of porous structure. With the increase of PCL content, The size and number of microscopic holes also increases. Conclusion By selecting different biomaterials and blending methods, the morphologies of the microspheres are changed to meet the different requirements of different drug delivery systems and tissue engineering on the performance and morphology of the carrier.